Tracy Kerzan
Critical Care Medicine · Vincennes, INNPI 1629529334
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.
Across 113 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$339
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$219
- Merck$184
- Mylan Specialty L.p.$158
- Boehringer Ingelheim$122
- Amgen$122
- plus $739 from 22 others
What the payments were for
- Food & beverage$1,883100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 19 | $339 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $219 |
| Merck | 12 | $184 |
| Mylan Specialty L.p. | 10 | $158 |
| Boehringer Ingelheim | 9 | $122 |
| Amgen | 7 | $122 |
| GSK | 6 | $83 |
| Insmed, Inc. | 5 | $81 |
| Bayer | 3 | $52 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $48 |
| Sanofi | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| AstraZeneca | 2 | $44 |
| Pfizer | 3 | $43 |
| Novo Nordisk | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Grifols USA, LLC | 2 | $27 |
| Pulmonx Corporation | 1 | $27 |
| Abbott | 1 | $23 |
| United Therapeutics Corporation | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Fresenius USA Marketing, Inc. | 1 | $13 |
How this compares
$1,883 in reported general payments places this provider in the 70th percentile of 158 critical care medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 21 | $187 |
| ClopidogrelClopidogrel Bisulfate | 15 | $172 |
| Azithromycin | 12 | $53 |
| Montelukast Sodium | 12 | $20 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Vincennes
- Vrushank PatelIndianapolis$142K
- Matthew KoscielskiSouth Bend$118K
- Christopher KnieseIndianapolis$44K
- Stanley NasrawayIndianapolis$34K
- Ismail Al-AniSouth Bend$25K
- Horia DraghiciuRichmond$21K
- Shashikumar GowdaTerre Haute$20K
- Laura RodriguezMerrillville$15K
- Ryan BoenteIndianapolis$15K
- Derrick FergusonBloomington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.